Trade United Therapeutics Corp - UTHR CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.40 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 296.27 |
| Open | 288.08 |
| 1-Year Change | 21.51% |
| Day's Range | 288.08 - 293.38 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 296.27 | 2.86 | 0.97% | 293.41 | 297.56 | 291.35 |
| Apr 23, 2025 | 292.99 | -0.81 | -0.28% | 293.80 | 298.38 | 291.52 |
| Apr 22, 2025 | 292.62 | 7.67 | 2.69% | 284.95 | 293.15 | 284.95 |
| Apr 21, 2025 | 283.75 | -1.20 | -0.42% | 284.95 | 291.05 | 281.10 |
| Apr 17, 2025 | 284.34 | 0.39 | 0.14% | 283.95 | 287.19 | 280.80 |
| Apr 16, 2025 | 284.89 | -0.01 | -0.00% | 284.90 | 288.30 | 281.88 |
| Apr 15, 2025 | 284.75 | 3.48 | 1.24% | 281.27 | 287.65 | 278.47 |
| Apr 14, 2025 | 284.16 | 0.66 | 0.23% | 283.50 | 285.41 | 278.29 |
| Apr 11, 2025 | 280.44 | 0.49 | 0.18% | 279.95 | 284.32 | 275.07 |
| Apr 10, 2025 | 278.64 | -6.31 | -2.21% | 284.95 | 287.39 | 269.95 |
| Apr 9, 2025 | 292.33 | 17.38 | 6.32% | 274.95 | 293.76 | 266.70 |
| Apr 8, 2025 | 279.68 | -19.34 | -6.47% | 299.02 | 299.95 | 276.04 |
| Apr 7, 2025 | 291.64 | 10.03 | 3.56% | 281.61 | 300.27 | 272.95 |
| Apr 4, 2025 | 291.97 | -8.07 | -2.69% | 300.04 | 305.92 | 290.29 |
| Apr 3, 2025 | 307.04 | 8.92 | 2.99% | 298.12 | 311.79 | 295.95 |
| Apr 2, 2025 | 312.19 | 8.91 | 2.94% | 303.28 | 312.79 | 300.56 |
| Apr 1, 2025 | 306.66 | 1.71 | 0.56% | 304.95 | 311.08 | 302.95 |
| Mar 31, 2025 | 308.09 | 5.64 | 1.86% | 302.45 | 308.96 | 297.97 |
| Mar 28, 2025 | 306.70 | -2.25 | -0.73% | 308.95 | 308.95 | 304.50 |
| Mar 27, 2025 | 307.82 | -3.04 | -0.98% | 310.86 | 314.41 | 307.46 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
United Therapeutics Company profile
About United Therapeutics Corporation
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells four commercial therapies in the United States to treat ulmonary arterial hypertension (PAH): Tyvaso (treprostinil) Inhalation Solution (Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso has also been approved to treat pulmonary hypertension associated with interstitial lung disease. It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin), which is approved for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). It also includes technologies designed supply of transplantable organs and tissues and improves outcomes for transplant recipients through regenerative medicine, three-dimensional (3-D) organ bioprinting, xenotransplantation and ex-vivo lung perfusion.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, United Therapeutics Corporation revenues increased 14% to $1.69B. Net income decreased 8% to $475.8M. Revenues reflect Tyvaso segment increase of 26% to $607.5M, Unituxin segment increase of 65% to $202.3M, United States segment increase of 11% to $1.56B, Rest-of-World segment increase of 70% to $121.3M. Net income was offset by IPR&D asset impairment charges increase from $0K to $113.4M (expense).
Equity composition
Common Stock $.01 Par, 06/11, 245M auth., 60,817,983 issd., less 2,503,657 shs. in Treas. @ $70.1M. Insiders control 1.10%. IPO: 6/17/99, 4,500,000 @ $12 by Deutsche Banc Alex. Brown. 09/09, 2-for-1 stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
1000 Spring St
SILVER SPRING
MARYLAND 20910
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com